Burris K D, Pacheco M A, Filtz T M, Kung M P, Kung H F, Molinoff P B
Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, USA.
Neuropsychopharmacology. 1995 Jul;12(4):335-45. doi: 10.1016/0893-133X(94)00099-L.
The affinities of D3 dopamine receptors for antagonists are similar to those of D2 receptors. D3 receptors have been reported, however, to have affinities nearly 100-fold higher than those of D2 receptors for some agonists, including (+/-)-7-hydroxy-n,n-dipropyl-aminotetralin (7-OH-DPAT) and quinpirole. This has led to the use of these agonists to try to identify functional responses mediated by D3 receptors in vivo. However, D2 receptors exist in multiple states having high and low affinities for agonists. The G protein-coupled state of D2 receptors is believed to be the functional state of these receptors. When receptors were labeled with the D2 receptor antagonist [125I]-(S)-3-iodo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5,6- dimethoxysalicylamide ([125I]-NCQ-298) under conditions that promote uncoupling of receptors from G proteins, the affinities of D3 receptors were approximately 130-fold higher than those of D2 receptors for 7-OH-DPAT and quinpirole. When receptors were labeled with the D2 receptor agonist [125I]-(R)trans-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'- propenyl)-amino]tetralin ([125I]-7-OH-PIPAT) under conditions that favor interactions of receptors with G proteins, the affinities of D3 receptors were less than sevenfold higher than the affinities of D2 receptors for the same drugs. Similarly, small differences in the affinities of D2 and D3 receptors for other agonists were seen when receptors were labeled with [125I]-7-OH-PIPAT. These data demonstrate that putative D3 receptor-selective agonists also interact with a high-affinity, G protein-coupled state of D2 receptors. The similarities in affinities of the agonist-preferring state of D2 and D3 receptors means that currently available agonists cannot be used to discriminate between behavioral effects mediated by D2 and D3 receptors.
D3多巴胺受体与拮抗剂的亲和力与D2受体相似。然而,据报道,D3受体对某些激动剂的亲和力比D2受体高近100倍,这些激动剂包括(±)-7-羟基-N,N-二丙基-氨基四氢萘(7-OH-DPAT)和喹吡罗。这使得人们使用这些激动剂来试图识别体内由D3受体介导的功能反应。然而,D2受体存在多种对激动剂具有高亲和力和低亲和力的状态。D2受体的G蛋白偶联状态被认为是这些受体的功能状态。当在促进受体与G蛋白解偶联的条件下用D2受体拮抗剂[125I] -(S)-3-碘-N- [(1-乙基-2-吡咯烷基)甲基] -5,6-二甲氧基水杨酰胺([125I] -NCQ-298)标记受体时,D3受体对7-OH-DPAT和喹吡罗的亲和力比D2受体高约130倍。当在有利于受体与G蛋白相互作用的条件下用D2受体激动剂[125I] -(R)反式-7-羟基-2- [N-丙基-N-(3'-碘-2'-丙烯基)-氨基]四氢萘([125I] -7-OH-PIPAT)标记受体时,D3受体对相同药物的亲和力比D2受体高不到7倍。同样,当用[125I] -7-OH-PIPAT标记受体时,D2和D3受体对其他激动剂的亲和力也存在微小差异。这些数据表明,假定的D3受体选择性激动剂也与D2受体的高亲和力G蛋白偶联状态相互作用。D2和D3受体的激动剂偏好状态的亲和力相似,这意味着目前可用的激动剂不能用于区分由D2和D3受体介导的行为效应。